StockNews.AI
A
StockNews.AI
84 days

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

1. Agilent launched the InfinityLab Pro iQ Series for advanced mass detection. 2. The series supports pharmaceutical, environmental, and academic sectors. 3. Dr. Mangelschots highlights enhanced sensitivity and efficiency in analyses. 4. Pro iQ Plus targets high-end applications requiring ultimate performance. 5. Innovation drives Agilent's commitment to scientific discovery and sustainable solutions.

6m saved
Insight
Article

FAQ

Why Bullish?

The launch addresses diverse analytical needs, likely increasing sales and market share. Historical instances, such as successful product launches leading to stock increases, further support this outlook.

How important is it?

Innovative product offerings can significantly influence Agilent's market position and financial performance realized over time.

Why Long Term?

Adoption in various sectors can create sustained revenue growth; similar launches historically led to long-term gains.

- Setting new standards for intelligent mass detection, sensitivity, and sustainability SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of its latest innovation in liquid chromatography (LC)-mass detection: the Agilent InfinityLab Pro iQ Series. This groundbreaking series includes the InfinityLab Pro iQ and the InfinityLab Pro iQ Plus, each tailored with distinct features and capabilities to meet the diverse analytical needs of modern laboratories. These advanced, intelligent systems are particularly well-suited for analyzing essential molecules such as therapeutic small molecules, oligonucleotides, peptides, and proteins. The Pro iQ Series is designed to serve a broad range of end markets, including pharmaceutical and biopharmaceutical industries, academic and government research institutions, environmental testing labs, food safety organizations, and the chemical and specialty materials sector. With its precision, sensitivity, and intelligent design, the series supports applications such as mass confirmation, impurity profiling, biomolecule characterization, trace contaminant detection, and compound purification—empowering scientists to achieve high-quality, reliable results in both routine and advanced analytical workflows. Dr. Iris Mangelschots, vice president and general manager of Agilent’s Liquid Phase Division, emphasized the strategic significance of the launch: “With the launch of the Pro iQ Series, Agilent is redefining the future of liquid chromatography detection and demonstrating our continuing commitment to delivering leading-edge solutions to help customers push the boundaries of scientific discovery. The advanced Pro iQ Series will empower researchers to achieve unprecedented levels of insight and efficiency, making complex analyses more accessible and sustainable.” The Pro iQ Series delivers exceptional performance and sensitivity, making it ideal for monitoring complex biomolecules and detecting impurities. Whether analyzing therapeutic small molecules, oligonucleotides, peptides, or proteins, the systems provide robust, high-resolution data to ensure accuracy, safety, and stability. The series also enables mass-based purification, allowing precise isolation of target compounds for downstream applications. The Pro iQ Plus system is engineered for high-end applications that demand ultimate sensitivity and performance. With an expanded mass range of m/z 2–3,000 and enhanced sensitivity through Agilent Jet Stream (AJS) technology, it supports both routine and trace-level detection of small and large molecules. These capabilities make it especially valuable in advanced R&D environments where extended analytical performance is critical. Both the Pro iQ and Pro iQ Plus systems are designed for operational efficiency and ease of use, enabling faster compound confirmation with greater specificity and selectivity than traditional UV detection—even for chromatographically unresolved compounds. The Pro iQ system, with a mass range of m/z 2–1,600, is optimized for small molecule analysis, making it a reliable choice for standard laboratory workflows. Jennifer Gushue, associate vice president of LC/MS Product Marketing at Agilent, highlighted the broad applicability of the new systems: “The versatility of the Pro iQ Series opens new possibilities across a wide spectrum of application areas—from pharmaceutical development and quality control to biotherapeutics, environmental testing, and academic research. Whether it's ensuring the purity of life-saving drugs, characterizing complex biomolecules—such as oligonucleotides and peptides—or advancing cutting-edge research, these systems deliver the precision, sensitivity, and intelligence today’s scientists need to solve tomorrow’s challenges.” About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook. More News From AGILENT TECHNOLOGIES INC

Related News